ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]
Clinical data | |
---|---|
Other names | BAY 86-5310; SH-T04211C; ZK283197 |
Routes of administration | By mouth[1] |
Drug class | Estrogen; Selective ERβ agonist |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
PubChem CID | |
PubChem SID | |
UNII | |
Chemical and physical data | |
Formula | C20H25FO2 |
Molar mass | 316.416 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit